|
1
|
Qin G, Shao JG, Zhu YC, Xu AD, Yao JH,
Wang XL, Qian YK, Wang HY, Shen Y, Lu P and Wang LJ:
Population-representative incidence of acute-on-chronic liver
failure: A prospective cross-sectional study. J Clin Gastroenterol.
50:670–675. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou WC, Zhang QB and Qiao L: Pathogenesis
of liver cirrhosis. World J Gastroenterol. 20:7312–7324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sebastiani G: Non-invasive assessment of
liver fibrosis in chronic liver diseases: Implementation in
clinical practice and decisional algorithms. World J Gastroenterol.
15:2190–2203. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen SL, Zheng MH, Shi KQ, Yang T and Chen
YP: A new strategy for treatment of liver fibrosis: Letting
MicroRNAs do the job. BioDrugs. 27:25–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Hou D, Chen X, Li D, Zhu L, Zhang
Y, Li J, Bian Z, Liang X, Cai X, et al: Exogenous plant MIR168a
specifically targets mammalian LDLRAP1: Evidence of cross-kingdom
regulation by microRNA. Cell Res. 22:107–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mentz RJ, Hernandez AF, Berdan LG, Rorick
T, O'Brien EC, Ibarra JC, Curtis LH and Peterson ED: Good clinical
practice guidance and pragmatic clinical trials: Balancing the best
of both worlds. Circulation. 133:872–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poynard T, Bedossa P and Opolon P: Natural
history of liver fibrosis progression in patients with chronic
hepatitis C. The OBSVIRC METAVIR, CLINIVIR, andDOSVIRC groups.
Lancet. 349:825–832. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trang T, Petersen JR and Snyder N:
Non-invasive markers of hepatic fibrosis in patients co-infected
with HCV and HIV: Comparison of the APRI and FIB-4 index. Clin Chim
Acta. 397:51–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vallet-Pichard A, Mallet V, Nalpas B,
Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S:
FIB-4: An inexpensive and accurate marker of fibrosis in HCV
infection. Comparison with liver biopsy and fibrotest. Hepatology.
46:32–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Castera L, Forns X and Alberti A:
Non-invasive evaluation of liver fibrosis using transient
elastography. J Hepatol. 48:835–847. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schumann G, Bonora R, Ceriotti F, Férard
G, Ferrero CA, Franck PF, Gella FJ, Hoelzel W, Jørgensen PJ, Kanno
T, et al: IFCC primary reference procedures for the measurement of
catalytic activity concentrations of enzymes at 37 degrees C.
International Federation of Clinical Chemistry and Laboratory
Medicine. Part 5. Reference procedure for the measurement of
catalytic concentration of aspartate aminotransferase. Clin Chem
Lab Med. 40:725–733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schumann G, Bonora R, Ceriotti F, Férard
G, Ferrero CA, Franck PF, Gella FJ, Hoelzel W, Jørgensen PJ, Kanno
T, et al: IFCC primary reference procedures for the measurement of
catalytic activity concentrations of enzymes at 37 degrees C.
International Federation of Clinical Chemistry and Laboratory
Medicine. Part 4. Reference procedure for the measurement of
catalytic concentration of alanine aminotransferase. Clin Chem Lab
Med. 40:718–724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin BX, Zhang YH, Jin WJ, Sun XY, Qiao GF,
Wei YY, Sun LB, Zhang WH and Li N: MicroRNA panels as disease
biomarkers distinguishing hepatitis B virus infection caused
hepatitis and liver cirrhosis. Sci Rep. 5:150262015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saldanha J, Gerlich W, Lelie N, Dawson P,
Heermann K and Heath A: WHO Collaborative Study Group: An
international collaborative study to establish a World Health
Organization international standard for hepatitis B virus DNA
nucleic acid amplification techniques. Vox Sang. 80:63–71. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu AX, Baron AD, Malfertheiner P, Kudo M,
Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T,
et al: Ramucirumab as second-line treatment in patients with
advanced hepatocellular carcinoma: Analysis of REACH trial results
by child-pugh score. JAMA Oncol. Sep 22–2016.(Epub ahead of
print).
|
|
21
|
Lee UE and Friedman SL: Mechanisms of
hepatic fibrogenesis. Best Pract Res Clin Gastroenterol.
25:195–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X,
Zhou X and Gan J: A serum microRNA panel as potential biomarkers
for hepatocellular carcinoma related with hepatitis B virus. PLoS
One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noetel A, Kwiecinski M, Elfimova N, Huang
J and Odenthal M: microRNA are central players in anti- and
profibrotic gene regulation during liver fibrosis. Front Physiol.
3:492012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Itoh T and Miyajima A: Liver regeneration
by stem/progenitor cells. Hepatology. 59:1617–1626. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Appourchaux K, Dokmak S, Resche-Rigon M,
Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M,
Boyer N, Vidaud M, et al: MicroRNA-based diagnostic tools for
advanced fibrosis and cirrhosis in patients with chronic hepatitis
B and C. Sci Rep. 6:349352016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roderburg C and Luedde T: Circulating
microRNAs as markers of liver inflammation, fibrosis and cancer. J
Hepatol. 61:1434–1437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharma S, Khalili K and Nguyen GC:
Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J
Gastroenterol. 20:16820–16830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai X, Zhang W, Zhang H, Sun S, Yu H, Guo
Y, Kou Z, Zhao G, Du L, Jiang S, et al: Modulation of HBV
replication by microRNA-15b through targeting hepatocyte nuclear
factor 1α. Nucleic Acids Res. 42:6578–6590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan HX and Tang H: Complex interactions
between microRNAs and hepatitis B/C viruses. World J Gastroenterol.
20:13477–13492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu FL, Jin WB, Li JH and Guo AG: Targets
for human encoded microRNAs in HBV genes. Virus Genes. 42:157–161.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bandiera S, Pernot S, El Saghire H, Durand
SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, et
al: Hepatitis C virus-induced upregulation of MicroRNA miR-146a-5p
in hepatocytes promotes viral infection and deregulates metabolic
pathways associated with liver disease pathogenesis. J Virol.
90:6387–6400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roderburg C, Urban GW, Bettermann K, Vucur
M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi
M, et al: Micro-RNA profiling reveals a role for miR-29 in human
and murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou Y, Sun L, Wang X, Zhou L, Li J, Liu
M, Wang F, Peng J, Gui X, Zhao H, et al: Heroin use promotes HCV
infection and dysregulates HCV-related circulating microRNAs. J
Neuroimmune Pharmacol. 10:102–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ciesla M, Skrzypek K, Kozakowska M, Loboda
A, Jozkowicz A and Dulak J: MicroRNAs as biomarkers of disease
onset. Anal Bioanal Chem. 401:2051–2061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marquez RT, Bandyopadhyay S, Wendlandt EB,
Keck K, Hoffer BA, Icardi MS, Christensen RN, Schmidt WN and
McCaffrey AP: Correlation between microRNA expression levels and
clinical parameters associated with chronic hepatitis C viral
infection in humans. Lab Invest. 90:1727–1736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morita K, Taketomi A, Shirabe K, Umeda K,
Kayashima H, Ninomiya M, Uchiyama H, Soejima Y and Maehara Y:
Clinical significance and potential of hepatic microRNA-122
expression in hepatitis C. Liver Int. 31:474–484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kerr TA, Korenblat KM and Davidson NO:
MicroRNAs and liver disease. Transl Res. 157:241–252. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lakner AM, Bonkovsky HL and Schrum LW:
microRNAs: Fad or future of liver disease. World J Gastroenterol.
17:2536–2542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burns DM, D'Ambrogio A, Nottrott S and
Richter JD: CPEB and two poly(A) polymerases control miR-122
stability and p53 mRNA translation. Nature. 473:105–108. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan
J, Gandhi CR and Li S: miR-122 regulates collagen production via
targeting hepatic stellate cells and suppressing P4HA1 expression.
J Hepatol. 58:522–528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Waidmann O, Köberle V, Brunner F, Zeuzem
S, Piiper A and Kronenberger B: Serum microRNA-122 predicts
survival in patients with liver cirrhosis. PLoS One. 7:e456522012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheung O, Puri P, Eicken C, Contos MJ,
Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA and Sanyal AJ:
Nonalcoholic steatohepatitis is associated with altered hepatic
MicroRNA expression. Hepatology. 48:1810–1820. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Du J, Niu X, Wang Y, Kong L, Wang R, Zhang
Y, Zhao S and Nan Y: MiR-146a-5p suppresses activation and
proliferation of hepatic stellate cells in nonalcoholic fibrosing
steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci Rep.
5:161632015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He Y, Huang C, Sun X, Long XR, Lv XW and
Li J: MicroRNA-146a modulates TGF-beta1-induced hepatic stellate
cell proliferation by targeting SMAD4. Cell Signal. 24:1923–1930.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pu W, Shang Y, Shao Q and Yuan X: miR-146a
promotes cell migration and invasion in melanoma by directly
targeting SMAD4. Oncol Lett. 15:7111–7117. 2018.PubMed/NCBI
|
|
47
|
Oksuz Z, Serin MS, Kaplan E, Dogen A,
Tezcan S, Aslan G, Emekdas G, Sezgin O, Altintas E and Tiftik EN:
Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p
could be used as novel non-invasive biomarkers for HCV-positive
cirrhosis and hepatocellular carcinoma. Mol Biol Rep. 42:713–720.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Haneklaus M, Gerlic M, O'Neill LA and
Masters SL: miR-223: Infection, inflammation and cancer. J Intern
Med. 274:215–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wan L, Yuan X, Liu M and Xue B:
miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit
proliferation of hep3B cells. Exp Ther Med. 15:2429–2435.
2018.PubMed/NCBI
|
|
50
|
Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z,
Wang JF, Zhang Z, Lu S, Huang X, et al: Plasma microRNA panel to
diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin
Oncol. 29:4781–4788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Waidmann O, Bihrer V, Pleli T, Farnik H,
Berger A, Zeuzem S, Kronenberger B and Piiper A: Serum microRNA-122
levels in different groups of patients with chronic hepatitis B
virus infection. J Viral Hepat. 19:e58–e65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Arataki K, Hayes CN, Akamatsu S, Akiyama
R, Abe H, Tsuge M, Miki D, Ochi H, Hiraga N, Imamura M, et al:
Circulating microRNA-22 correlates with microRNA-122 and represents
viral replication and liver injury in patients with chronic
hepatitis B. J Med Virol. 85:789–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou XL, Xu H, Liu ZB, Wu QC, Zhu RR and
Liu JC: miR-21 promotes cardiac fibroblast-to-myofibroblast
transformation and myocardial fibrosis by targeting Jagged1. J Cell
Mol Med. May 28–2018.(Epub ahead of print).
|
|
54
|
Liu G, Friggeri A, Yang Y, Milosevic J,
Ding Q, Thannickal VJ, Kaminski N and Abraham E: miR-21 mediates
fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J
Exp Med. 207:1589–1597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhu H and Fan GC: Role of microRNAs in the
reperfused myocardium towards post-infarct remodelling. Cardiovasc
Res. 94:284–292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thum T, Gross C, Fiedler J, Fischer T,
Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et
al: MicroRNA-21 contributes to myocardial disease by stimulating
MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
